(R)-N-(1-(5-(5-chloro-3-fluoro-2-(2-methyl-2H-tetrazol-5-yl)phenyl)-3-fluoropyridin-2-yl)ethyl)-4-hydroxytetrahydro-2H-pyran-4-carboxamide | 1075221-25-8

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 英文名称: (R)-N-(1-(5-(5-chloro-3-fluoro-2-(2-methyl-2H-tetrazol-5-yl)phenyl)-3-fluoropyridin-2-yl)ethyl)-4-hydroxytetrahydro-2H-pyran-4-carboxamide
• 英文别名: N-[(1R)-1-[5-[5-chloro-3-fluoro-2-(2-methyltetrazol-5-yl)phenyl]-3-fluoropyridin-2-yl]ethyl]-4-hydroxyoxane-4-carboxamide
• CAS: 1075221-25-8
• 化学式: C₂₁H₂₁ClF₂N₆O₃
• 分子量: 478.886
• InChiKey: LWKVMTCIFZPFNU-LLVKDONJSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.3
• 重原子数：
  33
• 可旋转键数：
  5
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.38
• 拓扑面积：
  115
• 氢给体数：
  2
• 氢受体数：
  9

反应信息

• 作为产物：
  描述：

  ((1R)-1-{5-[5-chloro-3-fluoro-2-(2-methyl-2H-tetrazol-5-yl)phenyl]-3-fluoropyridin-2-yl}ethyl)amine 、 4-羟基四氢吡喃-4-羧酸 在 1-羟基苯并三唑 、 盐酸-N-乙基-Nˊ-(3-二甲氨基丙基)碳二亚胺 、 三乙胺 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 生成 (R)-N-(1-(5-(5-chloro-3-fluoro-2-(2-methyl-2H-tetrazol-5-yl)phenyl)-3-fluoropyridin-2-yl)ethyl)-4-hydroxytetrahydro-2H-pyran-4-carboxamide
  参考文献：
  名称：

  Bradykinin B1 receptor antagonists: An α-hydroxy amide with an improved metabolism profile

  摘要：

  A series of carbo-and heterocyclic alpha-hydroxy amide-derived bradykinin B(1) antagonists were prepared and evaluated. A 4,4-difluorocyclohexyl alpha-hydroxy amide was incorporated along with a 2-methyl tetrazole in lieu of an oxadiazole to afford a suitable compound with good pharmacokinetic properties, CNS penetration, and clearance by multiple metabolic pathways. (C) 2008 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2008.07.126

文献信息

• Bradykinin B1 receptor antagonists: An α-hydroxy amide with an improved metabolism profile
  作者：Scott D. Kuduk、Ronald K. Chang、Robert M. DiPardo、Christina N. Di Marco、Kathy L. Murphy、Richard W. Ransom、Duane R. Reiss、Cuyue Tang、Thomayant Prueksaritanont、Douglas J. Pettibone、Mark G. Bock

  DOI：10.1016/j.bmcl.2008.07.126

  日期：2008.9

  A series of carbo-and heterocyclic alpha-hydroxy amide-derived bradykinin B(1) antagonists were prepared and evaluated. A 4,4-difluorocyclohexyl alpha-hydroxy amide was incorporated along with a 2-methyl tetrazole in lieu of an oxadiazole to afford a suitable compound with good pharmacokinetic properties, CNS penetration, and clearance by multiple metabolic pathways. (C) 2008 Elsevier Ltd. All rights reserved.